Danegaptide uniquely treats the underlying pathology in patients with diabetic retinopathy, which is present in approximately 30% of all diabetic patients.
Danegaptide stabilizes intercellular communication and strengthens both the retina's inner and outer blood barriers, which decreases vascular leakage and protection of capillary structures and helps remove the subretinal fluid.
Oral danegaptide therapy for these clinically proven conditions has the potential to be a more effective and less burdensome oral therapy for patients with diabetic retinopathy.